N. Parquet et al., New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients, BONE MAR TR, 25(9), 2000, pp. 965-968
Citations number
18
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Cyclosporin A (CsA) absorption is variable in bone marrow transplant (BMT)
patients compromising the efficacy of graft-versus-host disease prevention.
Neoral, a new microemulsion formulation of CsA which has an improved bioav
ailibility, increases intestinal absorption of the drug with less variable
pharmacokinetic parameters in non-BMT patients. In order to predict the bes
t dosage of Neoral when patients are switched from i.v. to oral administrat
ion we performed a randomised study comparing two oral doses, either the sa
me or twice the last i.v. dose used after BMT. Fourteen adults were randomi
sed around day 25 after BMT. Whole blood CSA concentrations were measured 2
and 12 h after the oral administration of Neoral on days 0, 7 and 14 to de
termine residual and maximum concentration, and modified whenever necessary
to maintain blood level CsA concentration within therapeutic range (150-25
0 ng/ml). We found that patients who received twice the last i.v. dose had
better concentrations than patients from the other group while toxicity was
identical in both groups. We conclude that doubling the last i.v. dose dur
ing the switch to oral administration of Neoral gives the best therapeutic
range concentration and should be recommended for graft-versus-host prevent
ion.